p53 mutations occur in approximately 50% of cancers, which make cancer cells less responsive to the genotoxic agents.42 Indeed, leukemia patients with p53 deficiency represent a group with a high resistance to radio- and chemotherapy and demonstrate the most aggressive disease courses.43 Therefore, activation of Lxn could sensitize p53-deficient tumor cells to radiation and chemotherapeutic agent, and potentiate their cytotoxicity, thus enhancing the efficacy of cancer treatment and reducing the relapse. The gene discussed is TP53; the disease is cancer.